1. Home
  2. Labeler Index
  3. Lupin Pharmaceuticals, Inc.
  4. 68180-267
  5. Product Images: Divalproex Sodium

Product Images Divalproex Sodium

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 8 images provide visual information about the product associated with Divalproex Sodium NDC 68180-267 by Lupin Pharmaceuticals, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Structure - f3c76444 51cb 49f3 81a4 1e0a6f0660f4 01

Structure - f3c76444 51cb 49f3 81a4 1e0a6f0660f4 01

Figure 2 - f3c76444 51cb 49f3 81a4 1e0a6f0660f4 02

Figure 2 - f3c76444 51cb 49f3 81a4 1e0a6f0660f4 02

Fig 2 - f3c76444 51cb 49f3 81a4 1e0a6f0660f4 03

Fig 2 - f3c76444 51cb 49f3 81a4 1e0a6f0660f4 03

This appears to be a graph or chart displaying the percentage reduction in CPS (unknown acronym) rate for patients taking Divalproex Sodium Delayed-Release Tablets compared to a placebo. The graph shows that 50% of patients experienced improvement, while the other half either saw no change or worsening. Not enough information is available to provide more context.*

Fig 3 - f3c76444 51cb 49f3 81a4 1e0a6f0660f4 04

Fig 3 - f3c76444 51cb 49f3 81a4 1e0a6f0660f4 04

This text appears to be a chart or graph showing the reduction in CPS (cycles per second) rate for patients receiving high and low doses of a treatment. It shows that 50% of patients experienced improvement in their CPS rate, while some experienced no change and others experienced worsening. The exact treatment, condition, or context for this data is not available.*

Figure 4 - f3c76444 51cb 49f3 81a4 1e0a6f0660f4 05

Figure 4 - f3c76444 51cb 49f3 81a4 1e0a6f0660f4 05

This text indicates the presence of two studies related to delayed-release tablets of Divalproex Sodium, with one of them including a placebo. No further information is provided.*

Fig 6 - f3c76444 51cb 49f3 81a4 1e0a6f0660f4 06

Fig 6 - f3c76444 51cb 49f3 81a4 1e0a6f0660f4 06

This is a description of Divalproex Sodium tablets manufactured by Lupin Pharmaceuticals Inc. The tablets are delayed-release type and are available in bottles containing 100 tablets, with each tablet containing 125mg of the active ingredient. The tablets are not to be accepted if the bottle seal is broken. The NDC number for this product is 68180-265-01. The text also includes dosage information and the manufacturer's address.*

Fig 7 - f3c76444 51cb 49f3 81a4 1e0a6f0660f4 07

Fig 7 - f3c76444 51cb 49f3 81a4 1e0a6f0660f4 07

This is a prescription medication called Divalproex Sodium Delayed-Release Tablets USP. Each tablet contains 250mg of the active ingredient, divalproex sodium equivalent to valproic acid. The tablets should be kept in a cool and dry place between 20-25°C. This medication is manufactured by Lupin Limited and comes in a container with 100 tablets. The NDC (National Drug Code) for this specific package is 68180-266-01. Usual dosage information is not available.*

Figure 8 - f3c76444 51cb 49f3 81a4 1e0a6f0660f4 08

Figure 8 - f3c76444 51cb 49f3 81a4 1e0a6f0660f4 08

This is medication information for Divalproex Sodium Delayed-Release Tablets sold by Lupin Pharmaceuticals. It shows the NDC (National Drug Code), the drug's active ingredient (divalproex sodium USP), and the strength (500 mg of valproic acid). The text also provides information about the drug's usual dosage, storage instructions, and manufacturer. The text is accompanied by a lot number and expiration date.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.